Asimov, the synthetic biology company focused on mammalian cell engineering, recently launched our industry-leading platforms for stable viral vector production (HEK293) and biologics manufacturing (CHO). Originally developed at MIT, our platform radically advances the design and manufacture of gene therapies and biologics. By integrating state-of-the-art genetic engineering, computational biology, and automation, Asimov enables breakthrough solutions to long-standing challenges in industry.